PersonGen BioTherapeutics (Suzhou) Co., Ltd.
2 clinical trials · 2 recruiting · INDUSTRY
Trials by PersonGen BioTherapeutics (Suzhou) Co., Ltd.
RECRUITINGEarly Phase 1NCT07312630
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid...
Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive...
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.Enrolling: 191 location
Non-Hodgkin Lymphoma (NHL)Acute Lymphoblastic Leukemia (ALL), Adult
RECRUITINGNCT06361745
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Main purpose: To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). Secondary purpose: To evaluate the...
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.Enrolling: 101 location
Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis+2